Generic Name : Canakinumab Pronunciation : KAN-a-KIN-ue-mab Therapeutic Classification : Monoclonal antibodies ICD Code : Y43.4♦ Safety Labeling Changes Approved By FDA
International- Ilaris. Why it is prescribed (Indications) : This medication is an interleukin-1 beta-blocker, prescribed for auto-inflammatory diseases known as cryopyrin-associated periodic syndrome (CAPS). It decreases interleukin-1 beta's activity. When it is not to be taken (Contraindications): Contraindicated in patients with severe infection, HIV/AIDS, hepatitis B or C, who are taking tumor necrosis factor (TNF) blocker, and known hypersensitivity.
Dosage & When it is to be taken : SC- Adult- The recommended dose is 150 mg for patients with body weight greater than 40 kg.
Child- The recommended dose is 15 to 40 kg with an inadequate response; the dose can be increased to 3 mg/kg. How it should be taken : It comes as a powder for injection (diluted with fluid) to be administered by a healthcare provider under the skin. Warnings and Precautions :
* Caution should be exercised in patients with history of autoimmune disorder, cancer, hepatitis B or C, tuberculosis, infection, flu-like symptoms, any allergy, who are taking other medications, during pregnancy and breast-feeding.
* It may cause dizziness, do not drive a car or operate machinery while taking this medication.
* Avoid contact with people who have infections.
* It should not be used in children less than 4 years old. Side Effects :
Most Common - Diarrhea, influenza, headache and nausea.
♦ Miscellaneous - Increased weight, musculoskeletal pain, fainting, stomach inflammation, nose inflammation, decrease in white blood cells.
* Avoid excess dosage. Storage Conditions :
Store it in refrigerator (2 to 8°C). Do not freeze it.
Comment & Contribute
Ask an Expert